REDWOOD CITY, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc.(NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced that Steve Basta, Chief Executive Officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 4:00 p.m. ET in New York, New York.
The fireside chat will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Replays of the webcast will be archived on the Company’s website for 30 days following the presentation.
About Menlo Therapeutics
Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The Company’s clinical development program for serlopitant includes ongoing Phase 3 studies for the treatment of pruritus associated with prurigo nodularis, an ongoing Phase 2 study for the treatment of pruritus associated with psoriasis, and a planned Phase 2 study for the treatment of chronic pruritus of unknown origin.
Media Contact: email@example.com
Investor Contact: firstname.lastname@example.org